This review provides the following:

  • information about the marketing of antipsychotics for¬†pediatric use
  • information about how¬†antipsychotics act on the brain
  • a review of¬†efficacy studies of antipsychotics for pediatric use
  • a review of¬†short-term and long-term risks and harms



Although the prescribing of atypical antipsychotics to children and adolescents took hold in the late 1990s and early 2000s, there is still a lack of good research on their short-term effectiveness. There is no evidence that the drugs provide a long-term benefit, for any condition. In a NIMH trial, the researchers concluded that “few” youth treated with antipsychotics benefit from the treatment at the end of one year. The drugs are known to cause a broad array of adverse effects, including metabolic dysfunction, diabetes, motor dysfunction, hormonal problems, poor global health and brain shrinkage. Withdrawal symptoms may be severe, and there is a risk that withdrawal can provoke psychotic and manic episodes.

You've landed on a MIA journalism article that is funded by MIA supporters. To read the full article, sign up as a MIA Supporter. All active donors get full access to all MIA content, and free passes to all Mad in America events.

Current MIA supporters can log in below.(If you can't afford to support MIA in this way, email us at [email protected] and we will provide you with access to all donor-supported content.)